HomeBUSINESS
BUSINESS

Mitsubishi Tanabe Sees Bullish Simponi, but Sales Slightly Lower on Price Revision
(May.11.2017)

Mitsubishi Tanabe Pharma said on May 10 that its revenue edged down in FY2016 compared to the previous year as strong sales of its rheumatoid arthritis (RA) drug Simponi (golimumab) and other priority products failed to cover the negative impact of a biennial price revision in April ...
(LOG IN FOR FULL STORY)

News Calendar